About Perfusion

Our Mission

We are leveraging our 19-million-dollar investment from the US military to commercialize a drug, PM-208, that treats capillary compression due to ischemia – a major unsolved problem in hemorrhagic shock as well as other ischemic injury including acute kidney injury, cardiac bypass disfunction and ischemic reperfusion injury. This is a patent protected drug with a simple formulation, simple mechanism of action strong pre-clinical safety profile. A drug that could help more than 4 million patients annually in the US with a market potential exceeding $10 billion dollars.

Partners graphic

Our Team

Gerald Eldering
Gerard Eldering​ Chief Executive Officer​ LinkedIn
Dr. Martin Mangino, PhD​
Dr. Martin Mangino, PhD​​ Inventor LinkedIn
Rob Collins
Rob Collins​ Chief Business Officer LinkedIn
Dr. Frank Booth​
Dr. Frank Booth​​ Chief Medical Officer​ LinkedIn
Curt Scribner​
Curt Scribner​​ Regulatory Lead ​ LinkedIn
Dave Hughes​
Dave Hughes​​ CMC Lead LinkedIn
Frank Del Greco
Frank Del Greco​ Project Manager LinkedIn
Dr. Loren Liebrecht​
Dr. Loren Liebrecht​​ Chief Research Medical Officer​ LinkedIn
Partners graphic

In addition to investor capital,
Perfusion Medical has received funding from​

Perfusion Medical works with a group of highly experienced contract research organizations ​and partners.

Accelerator programs and recognition​